Benefits of metronomic therapy targeting muscarinic receptors in breast cancer involves an increment in apoptosis/necrosis ratio and a decrement in ABCG2 expression.

SANCHEZ Y; ESPAÑOL A; LASERNA L; SALEM A; SALES ME

Mar del Plata

Congreso; -LXI Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica-LXIV Reunión Anual de la Sociedad Argentina de Inmunología-XLVIII Reunión Anual de la Sociedad Argentina de Farmacología Experimental; 2016

SAIC-SAI-SAFE

We demonstrated that muscarinic acetylcholine receptors (mAChR) are expressed in breast tumor cells while they are absent in non-tumorigenic murine and human breast cells. The addition of carbachol (CARB) during h stimulates cell death similarly to paclitaxel (PX), a cytostatic drug frequently used in breast cancer treatment. Applying the principles of metronomic therapy, a combination of low concentrations of CARB with PX promoted cell cytotoxicity generating a apoptosis/necrosis ratio 2:1 in murine mammary adenocarcinomas. In the human breast tumor cell line MCF-7, derived from a luminal tumor, the treatment with CARB (10-9M) and PX (10-11M) increased cell death by 47± % (p